Literature DB >> 34228365

A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions.

Alberto S Pappo1, Valerie McPherson2, Haitao Pan3, Fang Wang3, Lu Wang4, Teresa Wright5, Margaret Hussong6, Dana Hawkins2, Sue C Kaste7, Andrew M Davidoff8, Armita Bahrami4.   

Abstract

BACKGROUND: Childhood melanocytic tumors represent a diagnostic and therapeutic challenge, and additional research is needed to better define the natural history of these tumors.
METHODS: The authors developed a comprehensive, prospective registry called Molecular Analysis of Childhood Melanocytic Tumors for children and adolescents with an atypical Spitz tumor/Spitz melanoma (AST/SM), conventional or adult-type melanoma (CM), melanoma arising in a giant congenital nevus (MCM), or atypical melanocytic proliferation of other types (OT) to better define the clinical behavior of these lesions by incorporating an integrated clinicopathologic and molecular analysis using centralized pathology review and various platforms, including fluorescence in situ hybridization; array comparative genomic hybridization; and whole genome, exome, and capture targeted panels.
RESULTS: From May 2016 to November 2019, 70 children were enrolled with a median age at diagnosis of 9.1 years. Thirty-seven had AST/SM, 17 had CM, 4 had MCM, and 12 had OT. Patients with AST/SM were younger (median age, 7 years), and their tumor most commonly arose in the extremities and trunk. The most common gene rearrangements included MAP3K8 and ALK. None of the 33 patients who underwent a TERT promoter mutation analysis had a mutation, and all patients were alive. Among the CM patients, the median age was 13 years; 11 had a BRAFV600E mutation, and 7 had a TERT promoter mutation. Three patients died of their disease. All 4 patients with MCM harbored an NRASQ61 mutation and died of their disease. The OT group was heterogenous, and all patients survived.
CONCLUSIONS: The incorporation of an integrated clinicopathologic and genomic analysis identifies distinct subgroups of pediatric melanocytic lesions that have different clinical behaviors. The integration of this combined diagnostic modality can help to individualize diagnoses and treatments for these patients.
© 2021 American Cancer Society.

Entities:  

Keywords:  Spitz melanoma; TERT; atypical Spitz; melanoma; pediatric melanocytic lesions

Mesh:

Year:  2021        PMID: 34228365      PMCID: PMC8478797          DOI: 10.1002/cncr.33750

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.921


  23 in total

Review 1.  Melanoma.

Authors:  Dirk Schadendorf; Alexander C J van Akkooi; Carola Berking; Klaus G Griewank; Ralf Gutzmer; Axel Hauschild; Andreas Stang; Alexander Roesch; Selma Ugurel
Journal:  Lancet       Date:  2018-09-15       Impact factor: 79.321

2.  Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.

Authors:  Victor L Quan; Bin Zhang; Yongzhan Zhang; Lauren S Mohan; Katherine Shi; Annette Wagner; Lacey Kruse; Timothy Taxter; Nike Beaubier; Kevin White; Lihua Zou; Pedram Gerami
Journal:  J Invest Dermatol       Date:  2020-01-29       Impact factor: 8.551

3.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.

Authors:  David S Hong; Steven G DuBois; Shivaani Kummar; Anna F Farago; Catherine M Albert; Kristoffer S Rohrberg; Cornelis M van Tilburg; Ramamoorthy Nagasubramanian; Jordan D Berlin; Noah Federman; Leo Mascarenhas; Birgit Geoerger; Afshin Dowlati; Alberto S Pappo; Stefan Bielack; François Doz; Ray McDermott; Jyoti D Patel; Russell J Schilder; Makoto Tahara; Stefan M Pfister; Olaf Witt; Marc Ladanyi; Erin R Rudzinski; Shivani Nanda; Barrett H Childs; Theodore W Laetsch; David M Hyman; Alexander Drilon
Journal:  Lancet Oncol       Date:  2020-02-24       Impact factor: 41.316

4.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

5.  High frequency of BRAF mutations in nevi.

Authors:  Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

Review 6.  Pathology and genomics of pediatric melanoma: A critical reexamination and new insights.

Authors:  Armita Bahrami; Raymond L Barnhill
Journal:  Pediatr Blood Cancer       Date:  2017-09-12       Impact factor: 3.167

7.  TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.

Authors:  Seungjae Lee; Raymond L Barnhill; Reinhard Dummer; James Dalton; Jianrong Wu; Alberto Pappo; Armita Bahrami
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

8.  MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.

Authors:  Veronica A Kinsler; Patricia O'Hare; Thomas Jacques; Darren Hargrave; Olga Slater
Journal:  Br J Cancer       Date:  2017-03-02       Impact factor: 7.640

9.  Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome.

Authors:  Michael Rusch; Joy Nakitandwe; Sheila Shurtleff; Scott Newman; Zhaojie Zhang; Michael N Edmonson; Matthew Parker; Yuannian Jiao; Xiaotu Ma; Yanling Liu; Jiali Gu; Michael F Walsh; Jared Becksfort; Andrew Thrasher; Yongjin Li; James McMurry; Erin Hedlund; Aman Patel; John Easton; Donald Yergeau; Bhavin Vadodaria; Ruth G Tatevossian; Susana Raimondi; Dale Hedges; Xiang Chen; Kohei Hagiwara; Rose McGee; Giles W Robinson; Jeffery M Klco; Tanja A Gruber; David W Ellison; James R Downing; Jinghui Zhang
Journal:  Nat Commun       Date:  2018-09-27       Impact factor: 14.919

10.  Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.

Authors:  Erik A Williams; Meagan Montesion; Nikunj Shah; Radwa Sharaf; Dean C Pavlick; Ethan S Sokol; Brian Alexander; Jeff Venstrom; Julia A Elvin; Jeffrey S Ross; Kevin Jon Williams; Julie Y Tse; Mark C Mochel
Journal:  Mod Pathol       Date:  2020-06-01       Impact factor: 7.842

View more
  1 in total

1.  Morphologic features in a series of 352 Spitz melanocytic proliferations help predict their oncogenic drivers.

Authors:  Thibault Kervarrec; Daniel Pissaloux; Franck Tirode; Mahtab Samimi; Julien Jacquemus; Christine Castillo; Arnaud de la Fouchardière
Journal:  Virchows Arch       Date:  2021-11-11       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.